Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity

OBJECTIVE: The aim of this study was to explore the dose response of licogliflozin, a dual inhibitor of sodium/glucose cotransporter 1 (SGLT1) and 2 (SGLT2), by evaluating change in body weight in adults with overweight or obesity. METHODS: This dose‐response analysis evaluated change in body weight...

Descripción completa

Detalles Bibliográficos
Autores principales: Bays, Harold E., Kozlovski, Plamen, Shao, Qing, Proot, Pieter, Keefe, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217021/
https://www.ncbi.nlm.nih.gov/pubmed/32187881
http://dx.doi.org/10.1002/oby.22764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217021/
https://www.ncbi.nlm.nih.gov/pubmed/32187881
http://dx.doi.org/10.1002/oby.22764

Ejemplares similares